Broad-Spectrum Gramicidin S Derivatives with Potent Activity Against Multidrug-Resistant Gram-Negative ESKAPE Pathogens
Antibiotics · 22.04.2025 · 14 (5) · 423
DOI: 10.3390/antibiotics14050423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 22.04.2025. Verfasst von John T Kalyvas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Physics, Chemistry and Earth Sciences, The University of Adelaide, Adelaide, SA 5005, Australia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, Institute for Photonics and Advanced Sensing (IPAS).
Abstract (Originalsprache)
Background/Objectives: Multidrug-resistant Gram-negative ESKAPE pathogens, including E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii, pose a significant global health threat. Gramicidin S, a potent cyclic antimicrobial peptide, is largely ineffective against these bacteria, and its high haemolytic toxicity limits its clinical usage. This study reports on several novel gramicidin S analogues with improved efficacy and safety profiles against multidrug-resistant Gram-negative bacteria.
Methods
A total of 19 gramicidin S derivatives were synthesised using Fmoc-based solid-phase peptide synthesis with targeted substitutions to enhance cationicity and modulate hydrophobicity. Minimum inhibitory concentrations (MICs) were determined against standard Gram-negative and Gram-positive strains. Haemolytic toxicity and in vitro nephrotoxicity were evaluated using human red blood cells and HEK-293 cells, respectively. All peptides were characterised by RP-HPLC and HRMS.
Results
The selective incorporation of DArg and Trp significantly enhanced activity against Gram-negative bacteria while reducing cytotoxicity. Peptide 8 improved the therapeutic index (TI) against E. coli by 10-fold (MIC: 8 µg/mL; TI: 4.10) compared to gramicidin S (MIC: 32 µg/mL; TI: 0.38). Peptide 9 exhibited an 8-fold potency increase against K. pneumoniae and a 25-fold TI improvement. Peptide 19 enhanced activity against P. aeruginosa 8-fold over gramicidin S, while peptide 7 showed a 27-fold TI enhancement. All active peptides retained broad-spectrum activity against S. aureus, including MRSA.
Conclusions
The findings highlight the critical role of balancing hydrophobicity and cationicity to overcome species-specific resistance mechanisms. Our gramicidin S analogues demonstrate potent broad-spectrum activity with significantly reduced toxicity compared to the parent peptide, providing a robust platform for the development of new antibiotics against ESKAPE bacterial pathogens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, School of Physics, Chemistry and Earth Sciences, The University of Adelaide, Adelaide, SA 5005, Australia.
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia.
ORCID-Profile: Ornella Romeo
Förderung
- Australian Research Council
- Institute for Photonics and Advanced Sensing (IPAS)
Zitieren
APA
Kalyvas, J. T., Wang, Y., Romeo, O., Horsley, J. R., & Abell, A. D. (2025). Broad-Spectrum Gramicidin S Derivatives with Potent Activity Against Multidrug-Resistant Gram-Negative ESKAPE Pathogens. Antibiotics, 14(5), 423. https://doi.org/10.3390/antibiotics14050423
Vancouver
Kalyvas JT, Wang Y, Romeo O, Horsley JR, Abell AD. Broad-Spectrum Gramicidin S Derivatives with Potent Activity Against Multidrug-Resistant Gram-Negative ESKAPE Pathogens. Antibiotics. 2025;14(5):423. doi:10.3390/antibiotics14050423
BibTeX
@article{Kalyvas2025,
author = {Kalyvas, John T and Wang, Yifei and Romeo, Ornella and Horsley, John R and Abell, Andrew D},
title = {Broad-Spectrum Gramicidin S Derivatives with Potent Activity Against Multidrug-Resistant Gram-Negative ESKAPE Pathogens},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {5},
pages = {423},
doi = {10.3390/antibiotics14050423}
}
EUVIMED